1 / 10

Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence

Phase 2. Liver Transplantation. Treatment Naïve and Treatment Experienced. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence. Curry MP, et al. Gastroenterology. 2014;September 24. [ Epub ahead of print]. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence.

geoffrey-kirkland
Télécharger la présentation

Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 Liver Transplantation Treatment Naïve and Treatment Experienced Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  2. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Source: Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  3. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV RecurrenceStudy Design 92 screened 63 enrolled 61 dosed 46 underwent liver transplantation 43 with HCV RNA <LLOQ at transplantation These 43 patients analyzed for post-transplant virologic response Source: Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  4. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV RecurrenceStudy Design 0 12 24 48 Post-12 Week Required Duration Liver Transplant Sofosbuvir + Ribavirin N = 61 SVR12 Treatment for 12 to 48 weeks while awaiting liver transplant Drug DosingSofosbuvir: 400 mg once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  5. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Source: Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  6. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Virologic Response at Transplant and Post-Transplant 43/46 30/43 Source: Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  7. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Virologic Response at Transplant and Post-Transplant 43/46 31/43 31/43 30/43 Data for the 43 patientswith HCV RNA <25 IU/mL at time of transplant Source: Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  8. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Source: Curry MP, et al. Gastroenterology. 2014 September 17. [Epub Ahead of Print]

  9. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV RecurrenceConclusions Source: Curry MP, et al. Gastroenterology. 2014;September 24. [Epub ahead of print]

  10. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related